Ardelyx
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
400 5th Ave Ste 210, Waltham, Massachuse...Phone Number
(510) 745-1700Website
www.ardelyx.comRevenue
$427.7 MillionStock Symbol
ARDXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the management of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials.Explore more
Ardelyx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ardelyx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ardelyx had a recent Job posting/layoffs
Ardelyx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Ardelyx has new funding data
Check if Ardelyx has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ardelyx
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Ardelyx launches new products
Check out if Ardelyx is spiking on competitors!
Earning: See what the market has to say on Ardelyx recently announced quarterly report
Recommended Actions
Find VP level buyers at Ardelyx
Find 2 more new buyers
Compare Similar Companies to Ardelyx
Compare insights from companies similar to Ardelyx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105.8M
501-1,000
Public
$222.7M
1998
KH
Keith HoeyGlobal Vice President, , Value, Access & Distribution
Company Profile Activity
Activity Insights
Ardelyx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ardelyx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ardelyx.
Ardelyx financials insights
Gather financial insights about Ardelyx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series A
$26M
2011
Series B
$30M
2014
Multiple Rounds
$100.8M
2015
Share Placement
$77.8M
2016
Stock Offering
$80.4M
Share Placement
$110M
2018
Debt
$50M
2022
Debt
$27.5M
Other Financing Round
$20M
Ardelyx Tech Stack
A closer look at the technologies used by Ardelyx
See more technologies
Most Recent Scoops
Hiring Plans
Ardelyx has more open roles in Human Resources than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Open Position
Person-Based
Stake & Stock Ownership, Finance, Financial Transactions
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ardelyx
Sign Up For FreeTo access detailed company insights
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the management of hype... Read More
